Multidisciplinary Treatment

Cancers of the Colon, Rectum, and Anus

2017 Gastrointestinal Cancers Symposium

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Scott Kopetz


The International Watch & Wait database (IWWD) for rectal cancer: An update. Maxime van der Valk


Effect of sex on treatment outcomes in rectal cancer patients after neoadjuvant radiotherapy or chemoradiation: A combined analysis of Polish-1 and Polish-2 studies. Lucjan Wyrwicz


Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC). Herbert Hurwitz


CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209). Hans-Joachim Schmoll


Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance). Brendan John Guercio


Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment. Heinz-Josef Lenz


Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G. Naotoshi Sugimoto


Total neoadjuvant therapy for locally advanced rectal cancer. Andrea Cercek


Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC). David R. Fogelman


Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer. John M. Creasy


The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients. Luca Vigano


Unresectable colorectal cancer liver metastases treated with radioembolization: Updated survival analysis of the MORE study. Andrew S. Kennedy


Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial. Masato Nakamura


Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI. David Craig Portnoy


Association of delayed commencement of adjuvant chemotherapy (AC) with inferior survival in colon cancer patients with stage II and III diseases: A national population-based cohort study. Ik Yong Kim


The prognostic impact of surgical complications after combined modality treatment of rectal cancer: Long-term results of the CAO/ARO/AIO-94 trial. Thilo Sprenger


Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. Heinz-Josef Lenz


Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: Long-term survival results of the phase III UFT/LV study. Kiyoshi Hasegawa


Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Howard S. Hochster


Primary tumor location and survival in general population with metastatic colorectal cancer (mCRC). Shahid Ahmed


Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. Mohamed E. Salem


Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Herbert Hurwitz


BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer. Tim Larson


Neoadjuvant chemoradiation for locally advanced rectal cancer with fluoropyrimidine alone or intensified with oxaliplatin: A systematic review and meta-analysis. Ashlie Nadler


Longitudinal trajectory of cancer survivorship in patients with recurrent rectal cancer: Anatomy of recurrence in relation to quality of life and pain. Tarik Sammour


Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer. Irene S. Yu


A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). Masato Nakamura


Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease. Belinda Lee


Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial. Shukui Qin


Evolution in multimodality management of locally advanced rectal cancer. Campbell SD Roxburgh


Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC). Christina Sing-Ying Wu


Factors predictive of receiving neoadjuvant versus adjuvant chemoradiotherapy in locally advanced rectal cancer and the impact on overall survival. Alex Richard Coffman


Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials. Doreen Anuli Ezeife


Clinical outcomes of positive resection margins after endoscopic resection of early colorectal cancer. Jin-Oh Kim


The relationship between tumor location, tumor microenvironment, systemic inflammation, and cancer-specific survival in patients undergoing surgery for colon cancer. Meera Patel


Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis. Jessica Bogach


Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus. Arjun Gupta


Cost of colon cancer care: Results of nationwide inpatient sample (NIS) data. Pranshu Bansal


Effect of neoadjuvant IMRT for locally advanced rectal cancer on toxicity and pathologic response. John David


Impact of primary tumor sidedness on survival after resection of colorectal liver metastases (CRLM). Richard M. Lee-Ying


Survivorship after lower gastrointestinal cancer: Patient reported outcomes and planning for care. Melissa Frick


Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation. Oliver S Chow


Predictive value of PET/CT for pathological complete response and survival in patients with locally advanced rectal cancer. Eric C Sorenson


QTWIST analysis in the RECOURSE trial. Josep Tabernero


Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). Di Maria Jiang


Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study. Michel Ducreux


Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer. Amitesh Chandra Roy


Impact of country-specific health economic guidelines on cost-effectiveness (CE) estimates: An illustrative study of the CE of cetuximab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC). Gerard Harty


Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial). Dai Manaka


Incidence and outcomes of hospitalized patients with gastrointestinal malignancies and Clostridium difficile infection: A nationwide analysis. Arjun Gupta


Oncopre: A new chemotherapy benefit prediction algorithm to assist treatment decision making. Dimas Yusuf


Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies. Satoru Iwasa


A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC). Taroh Satoh


Preoperative chemoradiotherapy for advanced lower rectal cancer using SOX+Bev regimen. Jun Higashijima


Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT). Francesco Sclafani


Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Jonathan M. Loree


Primary tumor location as a prognostic and predictive factor in metastatic colorectal cancer (mCRC) treated with chemotherapy plus cetuximab: A retrospective analysis. Tamotsu Sagawa


Minimally invasive surgery to improve time to chemotherapy in colon cancer: Compliance to the American College of Surgeons Commission on Cancer quality metrics. Sinziana Dumitra


Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts). Axel Grothey


Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Alexis Diane Leal


Minimally invasive complete mesocolic excision and central vascular ligation for right colon cancer: Defining the radicality of central lymphadenectomy. Tarik Sammour


Association of adjuvant chemotherapy with improved overall survival for patients with locally advanced rectal cancer (LARC) who achieve a pathologic complete response (pCR) to neoadjuvant chemoradiation (nCRT). Danish Shahab


Effect of adjuvant chemotherapy following pathologic complete response on long-term survival in rectal cancer: A propensity score matched analysis. Ali Mokdad


Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer. Joel Lange


Impact of time to surgery in locally advanced rectal cancer patients. Madiha Naseem


Effect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102). Eric Van Cutsem


Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). Yoshito Komatsu


A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study. Eiji Shinozaki


Nationwide incidence, treatment, and outcomes of patients 80 years and older with rectal adenocarcinomas: Analysis of 5,076 patients. Richard John Cassidy


Current alignment between the practice patterns of gastrointestinal (GI) cancer clinical investigators (CI) and general medical oncologists (MO) in the treatment of metastatic GI cancers. Neil Love


Representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Jennifer Tseng


Utilization of primary chemoradiotherapy for anal squamous cell carcinoma in the elderly: An analysis of the NCDB. Benjamin Mitchell Motz


Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC). Belinda Lee


Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial. Kentaro Sakamaki


Ten-year survival data following resection of locally recurrent rectal cancer (LRRC). David Patrick Cyr


Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer. Katsutoshi Sekine


Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis. Yanqiao Zhang


Utilization of minimally invasive versus open colectomy for colon cancer and perioperative/short-term oncologic outcomes: Are we there yet? Jillian K. Smith


Comparative analysis of survival in colon cancer undergoing sentinel lymph node mapping versus conventional surgery based on number of positive lymph nodes. Sabarina Ramanathan


Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis. Ana Beatriz Kinupe Abrahao


Oncologic outcome and morbidity for elderly rectal cancer patients compared to younger patients after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study. Soo Yoon Sung


Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial. Antoine Adenis


Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer. Rachel Lee Delahunty


Demographic and clinical characteristics of patients with metastatic colorectal cancer (mCRC) associated with RAS testing from 129 million covered lives. Bruce A. Bach


The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients’ characteristics and safety analysis. John Souglakos


Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines. Tomoyuki Nagaoka


Overall survival of elderly metastatic colorectal cancer patients treated in second and third line by tumor site. Patricia Luhn


Fast track multidiscipline treatment versus conventional treatment for colorectal cancer: The results of a prospective randomized controlled study (FTMDT trial). Ke-Feng Ding


Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status. Katsuyuki Murai


Phase I/II trial of dose reduced capecitabine in elderly or frail patients with untreated advanced colorectal cancer. Daniel Adam Breadner


A prospective, randomized study of low molecular weight as supplemental therapy in metastatic colorectal cancer patients treated with FOLFIRI regimen and target agents. Hsiang-Lin Tsai


Hepatic artery therapies for unresectable colorectal liver metastases: Pooled survival analysis of 968 patients from TACE, yttrium-90, and HAI studies. Vitor Moutinho


Role of cetuximab in conversion therapy in advanced KRAS WT colorectal cancer with liver limited disease: A systematic review and meta-analysis. Michelle McMullen


Effect of multidisciplinary tumor conference on clinical management of rectal cancer. Georgios Karagkounis


Treatment sequencing and outcomes in synchronous metastatic rectal cancer. Madeleine Cornelia Strach


Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP). Fernando Rivera


Nonagenarian patients with metastatic colorectal cancer: Results from the South Australian metastatic colorectal cancer registry. Timothy Jay Price


An international patient-centered outcome measurement set for colorectal cancer. Harvey J. Mamon


Bevacizumab and its impact on survival for patients receiving subsequent ANTI-EGFR therapy: Results from the South Australian metastatic colorectal cancer registry. Timothy Jay Price


Reinduction of oxaliplatin-based chemotherapy after exposure to oxaliplatin in adjuvant setting for colorectal cancer. Seung-Hoon Beom


High-dose neoadjuvant intensity modulated radiotherapy/chemotherapy for distal rectal cancer followed by rectal sparing TEM. Albert S. DeNittis


Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. Alexis Diane Leal


Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. Shaan Dudani


A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer. Patrick McKay Boland


Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results. Laurent Mineur


Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects. Stefan Munker


An update on rectal cancer evaluation by magnetic resonance imaging in neoadjuvant therapy decision making: Retrospective case review. Alejandro Recio Boiles


Comparison of survival for left-sided KRASwt mCRC patients treated with anti-EGFR based therapy as compared to right-sided mCRC. Lubos B. Petruzelka


Patient reported distress is predictive of survival in patients with gastrointestinal tumors. Dale Alan Whitaker


Effect of extended postoperative recovery on long-term oncological outcomes. Elizabeth Poli


Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database. Tomasz Burzykowski


Immunotherapy using activated T cells with chemotherapy for metastatic colorectal cancer. Yoichiro Yoshida


Tumor sidedness, adjuvant chemotherapy (AC), and other factors affecting survival in patients with stage II colon cancer (CC-II). Shiva Kumar Reddy Mukkamalla


Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study. Holger Schulz


A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results. Takeshi Kato


Left versus right: Does location matter for refractory metastatic colorectal cancer (mCRC) patients in phase I clinical trials? Sukeshi R. Patel


Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases? Rika Kizawa


Impact of RAS testing on treatment duration among patients with metastatic colorectal cancer (mCRC). Bruce A. Bach


Analysis of clinical and research implications of expanding next-generation sequencing (NGS) libraries in the treatment options of gastrointestinal cancers in a large cancer center. Miguel Gonzalez Velez


Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. Atsushi Ohtsu


Intermittent maintenance treatment with bevacizumab in patients with metastatic colorectal cancer: A single centre experience. Eleonora Cerchiaro


Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis. Gong Chen


Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer—HGCSG1401. Yumiko Ota


The risk factors for vomiting and nausea in patients with oxaliplatin-based chemotherapy: Subgroup analysis of SENRI trial. Junichi Nishimura


Treatment strategy for colorectal liver metastases: Clinical impact of FOLFOXIRI regimen for unresectable cases. Yuji Morine


Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis. Daniel Adam Breadner


Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials. Daisuke Sakai


Self-reported adherence to regorafenib for metastatic colorectal cancer: A retrospective cohort study. Kazuyoshi Kawakami


Adjuvant treatment in extreme elderly patients with colorectal cancer. Marta Llopis Cuquerella


Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer. Matthew E. Burge


Prognostic impact of tumor (T) and lymph node (N) status in metastatic colon cancer (MCC): A validation study using the National Cancer Database (NCDB). Shiva Kumar Reddy Mukkamalla


Impact of robotic-assisted approach on lymphadenectomy for colorectal cancer. Reza Gamagami


Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). Eric Van Cutsem


ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients. Akie Watanabe


Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort. Vanessa Pachón Olmos


Comorbidities limiting recruitment of colorectal cancer (CRC) patients in early-phase trials. Narjust Duma


Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. Courtney C Cavalieri


Vitamin D levels among patients with colorectal cancer (CRC) from the San Francisco Bay area. Marissa Barbara Savoie


A retrospective analysis on the impact of preoperative neutrophil to lymphocyte ratio in stage II colon cancer. Deepna Jaiswal


The efficacy and safety of CapeOX plus bevacizumab therapy with a planned oxaliplatin stop-and-go strategy in patients with metastatic colorectal cancer: A multi-center, single-arm, phase II study (CCOG-0902 study). Yuuki Sunakawa


Protective effect of ursodeoxycholic acid against chemotherapy-induced mucositis. Seung Han Kim


Retrospective review of outcomes in patients (pts) with synchronous metastatic rectal cancer (mRC) receiving initial non-surgical management. Ella Torti


Evaluation and response of mucin pools in primary rectal cancer tissue during chemoradiotherapy (CRT). Hiroshi Miyakita


Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC). Takayuki Yoshino


Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months. Kaori Hayashi


Response rate and survival for patients with metastatic colorectal cancer from right-sided versus left-sided tumors, treated with first-line triplet chemotherapy with bevacizumab. Shouki Bazarbashi


Clinical trials versus clinical practice in colorectal cancer: Equivalent populations? Alejandra Magdaleno Cremades


Genomic-directed therapy of gastrointestinal cancers by comprehensive genomic profile (CGP): Clinical and genomic characteristics at the John Theurer Cancer Center (JTCC). Miguel Gonzalez Velez


Relations of changes in serum carcinoembryonic antigen (CEA) levels before and after chemoradiotherapy (CRT) and after surgery to histological response and outcomes in patients with locally advanced rectal cancer (LARC). Gota Saito


The utilization of multidiciplinary tumor boards (MDT) in clinical routine: Results of a health care research study focusing on patients with metastatic colorectal cancer. Kia Homayounfar


Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer. Xianglin Yuan


North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003). Toshiaki Shichinohe


Consolidation chemotherapy for locally advanced mid- or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: A multicenter, randomized controlled trial (KONCLUDE). Chang Woo Kim


Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform. Thomas J. George


KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma. Luis A. Diaz


Totally neoadjuvant chemoradiation therapy with mFOLFOX6 in locally advanced rectal cancer: A single arm phase II study (FOTAC). Jianwei Zhang


A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER. Akihito Tsuji


An open-label, randomized, controlled clinical trial to explore the curative effects between the treatment of capecitabine and andrographolide and the single capecitabine in the patients with pathological and/or histologic diagnosed unresectable, advanced, recurrent, and metastatic colorectal cancer. Yongqian Shu


Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial. Wenjing Wang